The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling.

Published in: Drug metabolism and personalized therapy (2022)

Neither chloroquine nor ivermectin reached therapeutic ELF levels in the presence of LPVr despite reaching toxic ivermectin plasma levels. PBPK modeling, guided with TDM in saliva, can be advantageous to evaluate the probability of reaching therapeutic ELF levels in the presence of PDDI, especially in home-treated patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
drug administration
prognostic factors
adverse drug
drug induced
electronic health record